Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring
A landmark study recently published in March 2025 by JCO Oncology Advances, demonstrates the potential of K-TRACKTM in monitoring treatment response and assessing recurrence risk among 623 Solid-Tumor Patients of six cancer types (lung, colorectal,...
VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
SHANGHAI and BOSTON, April 18, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate...